PO.MCB07.02 · 分子与细胞生物学

ABI1作为癌细胞中DNA结合转录调控因子的机制解析

Mechanistic dissection of ABI1 as DNA-binding transcriptional regulator in cancer cells

海报缩略图:ABI1作为癌细胞中DNA结合转录调控因子的机制解析
编号 7245 展板 12 时间 4/22 09:00–12:00 区域 Section 20 主讲 Kate Livingston, AS;BS
分会场 Chromatin Architecture and Regulatory Landscapes
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kate Livingston1, XIANG Li2, Kevin M. Lin1, Leszek Kotula1

1SUNY Upstate Medical University, Syracuse, NY,2UT Southwestern Medical Center, Dallas, TX

摘要 Abstract

中文摘要
背景:ABI1(Abelson互作蛋白-1)传统上被认为是一种在癌症生物学中具有稳态作用的多功能衔接蛋白。它在某些癌症(如前列腺癌)中作为肿瘤抑制因子发挥功能,但在其他癌症(例如乳腺癌)中表现出致癌活性。历史上,ABI1因其肌动蛋白-细胞骨架相关功能(包括细胞-细胞黏附、细胞运动和片状伪足形成)以及其在调控c-Abl、PI3K和Src等主要信号中枢中的作用而受到研究。我们最近的发现揭示了ABI1一项意料之外的功能:由保守的同源结构域同源区(HHR)介导的直接DNA结合。这一发现使我们假设ABI1可能作为一种此前未被认识的转录调控因子。在此,我们力图界定ABI1参与转录调控的分子机制。 方法:为确定序列特异性和基因组占据情况,我们使用HHR完整和HHR突变的ABI1构建体进行ChIP,并辅以使用纯化蛋白的体外DNA结合实验。亚细胞分级分离和染色质富集实验评估了ABI1的核定位及与染色质的关联。通过共免疫沉淀(co-IP)鉴定与ABI1相互作用的转录机器。比较表达野生型ABI1与HHR缺陷型DNA结合突变体细胞的RNA-seq界定了ABI1依赖性的转录输出。 结果:ABI1在体外和体内均结合DNA,并从整合的ChIP和体外结合分析中显示出可重现的序列基序。含有完整HHR结构域的ABI1变异体优先定位于核和染色质组分。co-IP研究确定ABI1为一个明确的转录复合物的组分。RNA-seq分析揭示,HHR介导的DNA结合是一个离散的ABI1依赖性转录程序所必需的。 结论:我们确定ABI1为一种新型DNA结合蛋白,具有序列偏好性以及通过其HHR结构域介导的转录调控能力。这些发现将ABI1的功能范围扩展到肌动蛋白调控和激酶信号传导之外,为ABI1驱动的转录调控提供了首个机制框架。
查看英文原文 English abstract
Background: ABI1 (Abelson interactor-1) is classically recognized as a multifunctional adaptor protein with homeostatic roles in cancer biology. It functions as a tumor suppressor in some cancer such as prostate cancer, yet exhibits oncogenic activity in other cancers such as for example breast cancer. Historically, ABI1 has been studied for its actin-cytoskeleton-associated functions-including cell-cell adhesion, cell motility, and lamellipodia formation-as well as its role in regulating major signaling hubs such as c-Abl, PI3K, and Src. Our recent findings reveal an unanticipated function of ABI1: direct DNA binding mediated by a conserved homeodomain homology region (HHR). This discovery led us to hypothesize that ABI1 may act as a previously unrecognized transcriptional regulator. Here, we sought to define the molecular mechanisms through which ABI1 contributes to transcriptional control. Methods: To determine sequence specificity and genomic occupancy, we performed ChIP using HHR-intact and HHR-mutant ABI1 constructs, complemented by in vitro DNA binding assays using purified proteins. Subcellular fractionation and chromatin enrichment assays assessed ABI1 nuclear localization and association with chromatin. ABI1-interacting transcriptional machinery was identified through co-immunoprecipitation (co-IP). RNA-seq comparing cells expressing wild-type ABI1 versus an HHR-defective DNA-binding mutant defined ABI1-dependent transcriptional outputs. Results: ABI1 binds DNA both in vitro and in vivo and displays reproducible sequence motifs from integrated ChIP and in vitro binding analyses. ABI1 variants containing an intact HHR domain localize preferentially to the nucleus and chromatin fractions. Co-IP studies identify ABI1 as a component of a defined transcriptional complex. RNA-seq analyses reveal that HHR-mediated DNA binding is required for a discrete ABI1-dependent transcriptional program. Conclusions: We identify ABI1 as a novel DNA-binding protein with sequence preference and transcriptional regulatory capacity mediated through its HHR domain. These findings expand the functional repertoire of ABI1 beyond actin regulation and kinase signaling, providing the first mechanistic framework for ABI1-driven transcriptional control.
利益披露 Disclosure
K. Livingston, None.. X. Li, None.. K. M. Lin, None.. L. Kotula, None.

← 返回 AACR 2026 检索